The Near Future of Pulmonary Arterial Hypertension Development

Part 1 of this interview can be found here.

Part 2 of this interview can be found here.

Part 3 of this interview can be found here.
With the recent success of different drug classes such as endothelin receptor antagonists (ERAs) and prostacyclin-receptor agonists detailed in large-scale, long-term trials such as SERAPHIN and GRIPHON, respectively, the pulmonary arterial hypertension (PAH) field has plenty data and patient populations to work with in the coming years.

In an interview with MD Magazine® while at the 2018 CHEST Annual Meeting in San Antonio, TX,  Gary Palmer, MD, MBA, Vice President of Medical Affairs for Actelion Pharmaceuticals and Victor Tapson, MD, Director of the Venous Thromboembolism & Pulmonary Vascular Disease Research Program at the Cedars-Sinai Medical Center, discussed how progressive studies on macitentan and selexipag will advance through real-world results and the ongoing SERAPHIN and GRIPHON trials.

They also detailed how those results may shape discussion at future CHEST meetings.

Leave a Reply

Your email address will not be published. Required fields are marked *